Vernalis, Genentech enter drug discovery deal
Genentech will make use of Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target. Vernalis CEO Ian Garland said the company is happy that Genentech chose
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
VelQuest is specialized in paperless lab execution systems supporting current Good Manufacturing Practices (cGMP) for FDA-regulated industries including pharmaceuticals and biotechnology organizations. Following the acquisition, Accelrys’ software portfolio
Quture’s new science and technology will introduce electronic performance measurement to empower hospitals and surgery centers to measure clinical performance on the InterSystems Corporation technology platform. Rural and